Page 1 | Search Results | ASH Clinical News | American Society of Hematology

1-20 of 690

Sort by

Sort Order Select

News

Nurse-Led Multidisciplinary Pathway Developed to Optimize Patient Journey in Acquired Hemophilia A

Katie Robinson

Abstract

View News titled, Nurse-Led Multidisciplinary Pathway Developed to Optimize Patient Journey in Acquired Hemophilia A

News

CHIP Drives Increased Mortality Unaltered by CAD Interventions

Khylia Marshall

Abstract

View News titled, CHIP Drives Increased Mortality Unaltered by CAD Interventions

News

Use of ACR/EULAR 2023 Criteria Results in Lower APS Diagnosis Rate Compared With Sydney Criteria

Leah Lawrence

Abstract

View News titled, Use of ACR/EULAR 2023 Criteria Results in Lower APS Diagnosis Rate Compared With Sydney Criteria

News

Prophylactic Anticoagulation Reduces Death, VTE in Patients With Cancer

Khylia Marshall

Abstract

View News titled, Prophylactic Anticoagulation Reduces Death, VTE in Patients With Cancer

News

Marstacimab Shows Long-Term Efficacy in Severe Hemophilia A, B Without Inhibitors

Katie Robinson

Abstract

View News titled, Marstacimab Shows Long-Term Efficacy in Severe Hemophilia A, B Without Inhibitors

News

Concizumab Reduced Annualized Bleeding Rates in Hemophilia A, B Regardless of Target Joints

Katie Robinson

Abstract

View News titled, Concizumab Reduced Annualized Bleeding Rates in Hemophilia A, B Regardless of Target Joints

News

Caplacizumab Combo a ‘Historic’ New Option for Non-Severe iTTP

Leah Lawrence

Abstract

View News titled, Caplacizumab Combo a ‘Historic’ New Option for Non-Severe iTTP

News

Use of GLP-1 Agonists in Diabetic Patients With PV, ET Reduces VTE, Mortality

Lara C. Pullen, PhD

Abstract

View News titled, Use of GLP-1 Agonists in Diabetic Patients With PV, ET Reduces VTE, Mortality

News

Half of Patients in EINSTEIN Jr. Trial Continue to Extended Anticoagulation Treatment

Lara C. Pullen, PhD

Abstract

View News titled, Half of Patients in EINSTEIN Jr. Trial Continue to Extended Anticoagulation Treatment

News

Daratumumab Shows Efficacy, Safety in Phase II Study of Previously Treated ITP

Katie Robinson

Abstract

View News titled, Daratumumab Shows Efficacy, Safety in Phase II Study of Previously Treated ITP

News

Five-Year Results of SEQUOIA Trial Show Maintenance of Benefit for Patients With Del(17p) Treatment-Naïve CLL Treated With Zanubrutinib

Anna Azvolinsky, PhD

Abstract

View News titled, Five-Year Results of SEQUOIA Trial Show Maintenance of Benefit for Patients With Del(17p) Treatment-Naïve CLL Treated With Zanubrutinib

News

Patients With CMML Show Durable Response to Lenzilumab, Azacitidine Combo

Leah Lawrence

Abstract

View News titled, Patients With CMML Show Durable Response to Lenzilumab, Azacitidine Combo

News

R-Pola-Glo Shows High Response Rates in Unfit, Older Patients With DLBCL

Leah Lawrence

Abstract

View News titled, R-Pola-Glo Shows High Response Rates in Unfit, Older Patients With DLBCL

News

Iptacopan Increases Hemoglobin in Paroxysmal Nocturnal Hemoglobinuria

Lara C. Pullen, PhD

Abstract

View News titled, Iptacopan Increases Hemoglobin in Paroxysmal Nocturnal Hemoglobinuria

News

Azacitidine Demonstrates Sustained Efficacy in VEXAS Syndrome

Khylia Marshall

Abstract

View News titled, Azacitidine Demonstrates Sustained Efficacy in VEXAS Syndrome

News

Another Potential Product for Fibrinogen Concentrate for Congenital Fibrinogen Deficiency

Ruth Jessen Hickman, MD

Abstract

View News titled, Another Potential Product for Fibrinogen Concentrate for Congenital Fibrinogen Deficiency

News

Small Activating RNA-Mediated Induction of HBG Gene Via In Vivo Delivery Shows Potential in SCD

Katie Robinson

Abstract

View News titled, Small Activating RNA-Mediated Induction of HBG Gene Via In Vivo Delivery Shows Potential in SCD

News

Trispecific Antibody Safe With High Efficacy in Phase I R/R MM Study

Katie Robinson

Abstract

View News titled, Trispecific Antibody Safe With High Efficacy in Phase I R/R MM Study

News

Ropeg May Provide New Treatment Option for Essential Thrombocythemia

Ruth Jessen Hickman, MD

Abstract

View News titled, Ropeg May Provide New Treatment Option for Essential Thrombocythemia

News

Subcutaneous Mosunetuzumab Could Be Administered in Community Setting to Patients With Follicular Lymphoma

Lara C. Pullen, PhD

Abstract

View News titled, Subcutaneous Mosunetuzumab Could Be Administered in Community Setting to Patients With Follicular Lymphoma

Update search

NARROW

Publications

Format

Topics

Date

Availability

Nurse-Led Multidisciplinary Pathway Developed to Optimize Patient Journey in Acquired Hemophilia A

CHIP Drives Increased Mortality Unaltered by CAD Interventions

Use of ACR/EULAR 2023 Criteria Results in Lower APS Diagnosis Rate Compared With Sydney Criteria

Prophylactic Anticoagulation Reduces Death, VTE in Patients With Cancer

Marstacimab Shows Long-Term Efficacy in Severe Hemophilia A, B Without Inhibitors

Concizumab Reduced Annualized Bleeding Rates in Hemophilia A, B Regardless of Target Joints

Caplacizumab Combo a ‘Historic’ New Option for Non-Severe iTTP

Use of GLP-1 Agonists in Diabetic Patients With PV, ET Reduces VTE, Mortality

Half of Patients in EINSTEIN Jr. Trial Continue to Extended Anticoagulation Treatment

Daratumumab Shows Efficacy, Safety in Phase II Study of Previously Treated ITP

Five-Year Results of SEQUOIA Trial Show Maintenance of Benefit for Patients With Del(17p) Treatment-Naïve CLL Treated With Zanubrutinib

Patients With CMML Show Durable Response to Lenzilumab, Azacitidine Combo

R-Pola-Glo Shows High Response Rates in Unfit, Older Patients With DLBCL

Iptacopan Increases Hemoglobin in Paroxysmal Nocturnal Hemoglobinuria

Azacitidine Demonstrates Sustained Efficacy in VEXAS Syndrome

Another Potential Product for Fibrinogen Concentrate for Congenital Fibrinogen Deficiency

Small Activating RNA-Mediated Induction of HBG Gene Via In Vivo Delivery Shows Potential in SCD

Trispecific Antibody Safe With High Efficacy in Phase I R/R MM Study

Ropeg May Provide New Treatment Option for Essential Thrombocythemia

Subcutaneous Mosunetuzumab Could Be Administered in Community Setting to Patients With Follicular Lymphoma

ASH Publications

American Society of Hematology

Update search

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only